Zollinger-Ellison syndrome screening

Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]

Zollinger-Ellison syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Zollinger-Ellison syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Zollinger-Ellison syndrome screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Zollinger-Ellison syndrome screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Zollinger-Ellison syndrome screening

CDC on Zollinger-Ellison syndrome screening

Zollinger-Ellison syndrome screening in the news

Blogs on Zollinger-Ellison syndrome screening

Directions to Hospitals Treating Zollinger-Ellison syndrome

Risk calculators and risk factors for Zollinger-Ellison syndrome screening

Overview

There is insufficient evidence to recommend routine screening for Zollinger-Ellison syndrome.

Screening

  • The single best screening test for Zollinger-Ellison syndrome (ZES) is by measuring fasting serum gastrin levels.
  • At the time of the test, it is advised not to take gastric antisecretory medications.
  • Serial multiple measurements on different days have to be performed because, fasting gastrin levels can fluctuate from day to day and can appear to be normal.
  • Normal levels of serum gastrin in untreated ZES are extremely rare (<1%)
  • Multiple endocrine neoplasia-type 1 (MEN 1) syndrome should be suspected if serum calcium levels are elevated.

References

Template:WH Template:WS